Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Express Scripts

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Abstract:Benzene-ring substituted (2-methylhydrazino)-methyl-benzene compounds and intermediates therefore are described. The former compounds are useful as cytostatic agents and, particularly, inhibit the growth of transplantable tumors in both mice and rats. Thus, they are active, for example, against Walker tumors, Ehrlich carcinoma and Ehrlich ascites carcinoma.
Inventor(s): Bollag; Werner (Basel, CH), Gutmann; Hugo (Reinach/Baseland, CH), Hegedus; Balthasar (Binningen, CH), Kaiser; Ado (Neufrenkendorf, CH), Langemann; Albert (Binningen, CH), Muller; Marcel (Frenkendorf, CH), Zeller; Paul (Allschwil, CH)
Assignee: Hoffmann-LaRoche Inc. (Nutley, NJ)
Filing Date:Jun 04, 1970
Application Number:05/043,572
Claims:1. A compound selected from the group consisting of compounds of the formula ##SPC6##

and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.8 is hydrogen R.sub.9 is selected from the group consisting of, carbamoyl, lower alkylcarbamoyl and hydroxy-lower alkylcarbamoyl.

2. A compound in accordance with claim 1, wherein R.sub.8 is hydrogen and R.sub.9 is carbamoyl.

3. A compound in accordance with claim 1, wherein R.sub.8 is hydrogen and R.sub.9 is lower alkylcarbamoyl.

4. A compound as in claim 1 which is 1-methyl-2-(4-ureido-benzyl)-hydrazine.

5. A compound as in claim 1 which is 1-methyl-2-[4-(3-n-butyl-ureido)-benzyl]-hydrazine.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: